David C Fisher - Dana-Farber Cancer Institute

基本信息

浏览量：94

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 149 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Long‐term Results of a Phase 1/1b Study of Ibrutinib Plus Umbralisib for Relapsed/refractory Chronic Lymphocytic Leukemia

Christine E Ryan,Yue Ren,Svitlana Tyekucheva,Jon E Arnason,Adam M Boruchov,Caron A Jacobson,David C Fisher,Hari Miskin,Peter Sportelli,Jennifer R Brown,Matthew S Davids

HemaSphereno. 1 (2025): n/a-n/a

引用0浏览0WOS引用

Longitudinal Patient-Reported Outcomes in Older Adults with Aggressive Lymphomas Receiving Chemoimmunotherapy

P Connor Johnson,Jeremy S Abramson,Ann S LaCasce,Philippe Armand,Jeffrey Barnes,Reid W Merryman,Jacob Soumerai,Ephraim Hochberg,Ronald W Takvorian,Caron A Jacobson,Jennifer L Crombie,David C Fisher, Joel Schwartz,Robb S Friedman, Julia Stacey,Daniel Yang, Bridget Coffey, Netana Markowitz,Oreofe O Odejide,Areej El-Jawahri

Journal of the National Comprehensive Cancer Network JNCCNno. 3 (2025)

引用0浏览0WOS引用

A Real-World Comparison of Commercial Use Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-cell Lymphoma

Andrew Looka,David A. Qualls, Daniel Matthews,Robert A. Redd,Christopher Sakellis,Caitlyn Duffy, Jamie Dela Cruz,Anna Saucier,Philippe Armand,Jennifer L. Crombie,David C. Fisher,Eric D. Jacobsen,Austin I. Kim,Ann S. LaCasce,Reid W. Merryman,Erin M. Parry,Caron A. Jacobson

Blood advancesno. 3 (2025): 455-462

引用0浏览0WOS引用

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S Davids,Christine E Ryan,Benjamin L Lampson,Yue Ren,Svitlana Tyekucheva,Stacey M Fernandes,Jennifer L Crombie,Austin I Kim,Matthew Weinstock,Josie Montegaard, Heather A Walker, Claire Greenman,Victoria Patterson,Caron A Jacobson,Ann S LaCasce,Philippe Armand,David C Fisher, Steve Lo,Adam J Olszewski,Jon E Arnason,Inhye E Ahn,Jennifer R Brown

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 7 (2024): 788-799

引用0浏览0WOS引用

Clonal Evolution During Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan,Binu Kandathilparambil Sasi,Elizabeth F. Cohen,Kiyomi Mashima, Hannah Cormier,Stacey M. Fernandes,Samantha J. Shupe, Roberta Santos Azevedo,Mariia Mikhaleva,Philippe Armand,David C. Fisher,Matthew S. Davids,Inhye E. Ahn,Michael Y. Tolstorukov,Mark A. Murakami,Jennifer R. Brown

Bloodno. Supplement 1 (2024): 4611-4611

引用0浏览0引用

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn,Yue Ren,David C. Fisher,Austin I. Kim, Nancy E. Kaddis,Jon E. Arnason, John P. Winters,Sobana Balasubramanian, Heather A. Walker,Victoria Patterson,Stacey M. Fernandes,Svitlana Tyekucheva,Matthew S. Davids,Jennifer R. Brown

Bloodno. Supplement 1 (2024): 1874-1874

引用0浏览0引用

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Matthew S. Davids,Christine E. Ryan,Yue Ren,Liam Hackett, Jeremy Zhang,Svitlana Tyekucheva,Stacey M. Fernandes,Jennifer L. Crombie,Austin I. Kim,Matthew Weinstock,Josie Montegaard, Heather A. Walker, Claire Greenman,Victoria Patterson,Caron A. Jacobson,Ann S. LaCasce,Philippe Armand,David C. Fisher, Steve Lo,Adam J. Olszewski,Jon E. Arnason,Inhye E. Ahn,Jennifer R. Brown

Bloodno. Supplement 1 (2024): 1865-1865

引用0浏览0引用

Primary Cutaneous EBV+ Extranodal NK/T‐cell Lymphoma of Gamma/delta T‐cell Lineage in the Posttransplantation Setting

Jessica F. Williams,Fabienne M. Lucas, Ruben D. Carrasco,Scott B. Lovitch,David C. Fisher,Thomas S. Kupper,Sam Sadigh

JOURNAL OF CUTANEOUS PATHOLOGYno. 10 (2024): 777-782

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn